Arina-1 is a nebulized therapy focused on chronic inflammatory airways diseases that is being evaluated as a twice daily nebulized therapy. Currently in pre-clinical development, Renovion is seeking FDA approval for Arina-1 to become the first FDA-approved therapy for lung transplant patients.


About 2,000 patients a year receive a lung transplant. The rate of survival for patients who have received a lung transplant remains the lowest for all solid organ transplants. Unlike other solid organ transplants, the rate of survival has remained the same for lung transplant over the last 15 years.


Lung Transplant Survival Rates

One-year survival rate: 80%

Five-year survival rate: 60%

Ten-year survival rate: 20%


There is a great need for therapies able to alter the course of disease for this small group of patients. We believe Arina-1 can be that therapy. To date, the therapy has been used successfully in three patients (one CF, one bilateral lung transplant with CF and one asthma) under compassionate-use IND.



With success in lung transplant, we hope to be able to provide a therapy to other patient populations, such as COPD and asthma.